Emergence of raltegravir-resistant HIV-1 in the central nervous system

International Journal of STD and AIDS

Volumn 21, Issue 12, 2010, Pages 840-841

  Watanabe, K ^a   Honda, M ^a   Watanabe, T ^a   Tsukada, K ^a   Teruya, K ^a   Kikuchi, Y ^a   Oka, S ^a   Gatanaga, H ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Cerebrospinal fluid; HIV; Integrase; Q148R; Raltegravir; Resistant

Indexed keywords

ABACAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AMNESIA; ARTICLE; ASTHENIA; CASE REPORT; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERESTHESIA; MALE; MOOD CHANGE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; VIRUS DETECTION; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MALE; PLASMA; PYRROLIDINONES;

EID: 79551705184     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009283     Document Type: Article

References (7)

1. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54
2. Lennox J, DeJesus E, Lazzarin A, et al. STARTMRK, a phase III study of the safety & efficacy of raltegravir (RAL)-based vs efavirenz (EFV)-based combination therapy in treatment-naïve HIV-infected patients [abstract H-896a]. In: Program and Abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2008
3. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-65
4. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008;16:138-45
5. Calcagno A, Banora S, Bertucci R, et al. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. AIDS 2010;24:931-32
6. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008;83:293-9
7. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF) - penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005;41:1787-93 (Pubitemid 41759866)